The epidermal growth factor receptor (EGFR) is a 170-kDa membrane-anchored protein tyrosine kinase that has been implicated in tumorigenesis. Protein kinases are targets for the treatment of numerous diseases including cancer, inflammatory disorders, and diabetes. There are 518 protein kinases that have a shared catalytic domain as far as structure, yet the regulation of their catalysis is variable.
The receptors in this family (ErbB/HER) consist of four tyrosine kinases that are structurally similar and include (EGFR; HER1 or ErbB-1), HER2/neu or ErbB-2, HER3 or ErbB-3, and HER4 or ErbB-4. All share an extracellular domain, an intracellular tyrosine kinase, and a transmembrane domain. Ligands such as transforming growth factor (TGF)-alpha or epidermal growth factor (EGF) activate the EGFR, resulting in its dimerization or heterodimerization with other receptors that are closely related, such as HER2/neu. Phosphorylation of these receptors through their tyrosine kinase domains leads to the recruitment of downstream effectors and activation of proliferation and cell-survival signals (Figure 1). This process appears to be overactive in malignancy. An important signaling route of the ErbB family is the Ras-Raf-MAP-kinase pathway. Through activation of Ras, a multistep cascade of phosphorylation is initiated; this leads to activation of the MAPKs ERK1 and ERK2,[4,5] both of which are linked to cell proliferation, transformation, and survival in laboratory studies.
We now have a better understanding of the structure of EGFR as well as mutations encountered in human cells because of data from the human genome project. It is of note that EGFR signaling may be affected by mechanisms other than EGFR expression. Mutation in the EGFR has been observed in a variety of tumors. The EGFRvIII mutant lacks the external ligand-binding domain but has a tyrosine kinase that is constitutively activated.
The ErbB network is key to important signaling pathways and has been preserved throughout evolution. Research in knockout and transgenic mice has clarified some of its important functions. Inactivation of the ErbB1 subtype seems to impair epithelial development such as tooth growth and eye opening.[9,10] ErbB1 seems to play an important role in differentiation of epithelial components of skin, lung, pancreas, and gastrointestinal tract. Mice that lack expression of TGF-alpha (an EGF ligand), have abnormalities in eye, skin, and hair development.
Although expressed in nonmalignant cells, the EGFR is highly expressed in a variety of tumors, and its expression is correlated with poor response to treatment and poor survival. Its activation has been shown to promote tumor proliferation, angiogenesis, as well as metastases and invasion.[8,13] It was earlier suggested that abnormal EGFR signaling is correlated with advanced disease, poor response to chemotherapy, and poor prognosis.[14,15] Human malignancies use several mechanisms that activate the EGF pathway, including overproduction of ligands, overproduction of receptors, or constitutive activation of receptors.[16,17] More recent data, however, indicate that overexpression of EGFR in non-small-cell lung cancer (NSCLC) may not be correlated with poor outcome. EGFR is overexpressed in 40% to 80% of NSCLC cases and numerous other epithelial cancers.
Similar chemical characteristics of EGFR in humans and mice indicate its preservation throughout a long evolutionary process. Radioimmunoassays have shown that EGFR is present in various body fluids including urine, saliva, amniotic fluid, and plasma. EGF has been shown to promote the growth of different cell types in tissue cultures including fibroblasts, mammary epithelium, and vascular endothelium.
The receptor is composed of a single chain with an outer portion that forms an EGF-binding domain (Figure 1). When the multipart portion of the receptor binds to EGF, it changes shape, allowing the receptor to dimerize with other receptors. The inner part of the receptor, which is a tyrosine kinase enzyme, is activated upon dimerization and adds phosphate groups to the tyrosine residues. This initiates a signaling cascade intracellularly that ultimately promotes DNA synthesis and cell growth. The growing information about the structure and function of this receptor has promoted the development and discovery of new anticancer drugs blocking the action of EGFR from both ends.
The potency of intracellular signaling seems to be determined by the ligand and which intracellular sites are autophosphorylated. The PI3K-activated AKT pathway and P70S6/P85S6K have different activation potencies that probably depend on the type of receptor (ErbB1/2/3/4). Several pathways including the MAPK pathway, the stress-activated protein kinase pathway, protein kinase C, and Akt are simultaneously activated. These lead to activation of different transcription programs in the nucleus. The result is activation of cell division and migration, both of which are characteristics of tumor cells. There appear to be other signaling pathways that are also integrated into the ErbB network including hormonal pathways, neurotransmitters, lymphokines, and stress inducers (Figure 1).
Tyrosine kinase inhibitors (TKIs) have been studied extensively in tissue culture of transformed cells and in animal models. They have been shown to inhibit receptor phosphorylation as well as tumor growth, invasion, and adhesion. They have also been shown to reverse cancer cells to phenotypically differentiated cells and hence reverse the process of transformation. Some quinazoline derivatives have been shown not only to compete with adenosine triphosphate but also to promote the formation of EGFR dimers that are inactive, and in the absence of ligands. Whether this property in these particular agents has any clinical implications is not yet known.
The author(s) have no significant financial interest or other relationship with the manufacturers of any products or providers of any service mentioned in this article.
1. Manning G, Whyte DB, Martinez R, et al: The protein kinase complement of the human genome. Science 298:1912-1934, 2002.
2. Jorissen RN, Walker F, Pouliot N, et al: Epidermal growth factor receptors: Mechanisms of activation and signaling. Exp Cell Res 284:31-53, 2003.
3. Noble MEM, Endicott JA, Johnson LN: Protein kinase inhibitors: Insights into drug design from structure. Science 303:1800-1804, 2004.
4. Alroy I, Yarden Y: The Erb signaling network in embryogenesis and oncogenesis: Signal diversification through combinational ligand-receptor interactions. FEBS Lett 410:83-86, 1997.
5. Lewis TS, Shapiro PS, Ahn NG: Signal transduction through MAP kinase cascades. Adv Cancer Res 74:49-139, 1998.
6. Ciesielski MJ, Fenstermarker RA: Structure of the epidermal growth factor receptor gene and intron recombination in human gliomas. Curr Genom 4:1-12, 2003.
7. Arteaga C: Epidermal growth factor receptor dependence in human tumors: More than just expression? Oncologist 7:31-39, 2002.
8. Wells A: The epidermal growth factor receptor (EGFR)-a new target in cancer therapy. Signal 1:4-11, 2000.
9. Miettinen PJ, Berger JE, Meneses J, et al: Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 376:337-341, 1995.
10. Threadgill DW: Targeted disruption of mouse EGF receptor: Effect of genetic background on mutant phenotype. Science 269:230-234, 1995.
11. Mann GB, Fowler KJ, Gabriel A, et al: Mice with null mutations of the TGF alpha gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation. Cell 73:249-261, 1993.
12. Brabender J, Danenberg KD, Metzger R, et al: Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 7:1850-1855, 2001.
13. Woodburn JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82:241-250, 1999.
14. Chen Z, Ke LD, Yuan XH, et al: Correlation of cisplatin sensitivity with differential alteration of EGFR expression in head and neck cancer cells. Anticancer Res 20:899-902, 2000.
15. D’Amico TA, Massey M, Herndon JE, et al: A biologic risk model for stage I lung cancer: Immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 117:736-743, 1999.
16. Scher HI, Sarkis A, Reuter V, et al: Changing pattern of expression of the epidermal growth factor receptorand transforming growth factor alpha in the progression of prostatic neoplasms. Clin Cancer Res 1:545-550, 1995.
17. Gorgoulis V, Aninos D, Mikou P, et al: Expression of EGF, TGF-alpha and EGFR in squamous cell lung carcinomas. Anticancer Res 12:1183-1187, 1992.
18. Janas M, Bailey LR, Schmidt K, et al: Evaluation of epidermal growth factor receptor (EGFR) as a prognostic factor for survival in non-small cell lung Cancer (NSCLC) patients treated with platinum based chemotherapy as first line treatment (abstract 7024). Proc Am Soc Clin Oncol 23:619, 2004.
19. Arteaga CL: ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res 284:122-130, 2003.
20. Carpenter G, Cohen S: Epidermal growth factor. Annu Rev Biochem 48:193-216, 1979.
21. O’Keefe E, Hollenberg MD, Cuatrecasas P: Epidermal growth factor, characteristics of specific binding in membranes from liver, placenta, and other target tissues. Arch Biochem Biophys 164:518-526, 1974.
22. Carpenter G: Epidermal growth factor: Biology and mechanism of action. Birth Defects Orig Artic Ser 16:61-72, 1980.
23. Soltoff SP, Cantley LC: p120cbl is a cytosolic adapter protein that associates with phosphoinositide 3-kinase in response to epidermal growth factor in PC12 and other cells. J Biol Chem 271:563-567, 1996.
24. Carpenter G: Employment of the epidermal growth factor receptor in growth factor independent signaling pathways. J Cell Biol 146:697-702, 1999.
25. Woodburn JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82:241-250, 1999.
26. Nelson JM, Fry DW: Cytoskeletal and morphological changes associated with the specific suppression of the epidermal growth factor receptor tyrosine kinase activity in A431 human epidermoid carcinoma. Exp Cell Res 233:383-390, 1997.
27. Arteaga CL, Ramsey TT, Shawer LK, et al: Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site. J Biol Chem 272:23247-23254, 1997.
28. Mendelsohn J, Baselga J: The EGF receptor family as targets for cancer therapy. Oncogene 19:6550-6565, 2000.
29. Wu X, Fan Z, Masui H, et al: Apoptosis induced by anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell lineand its delay by insulin. J Clin Invest 95:1897-1905, 1995.
30. Perrotte P, Matsumoto T, Inoue K, et al: Anti-epidermal growth factor receptor antibdy C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 5:257-265, 1999.
31. Ciardiello F, Caputo R, Bianco R, et al: Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor tyrosine kinase inhibitor. Clin Cancer Res 7:1459-1465, 2001.
32. Mandal M, Adam L, Wang R-A: Inhibition of p-21 activated kinase 1, directional cell motility and invasion of growth factor activated human cancer cells by selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 (‘Iressa’) (abstract 786). Proc Am Assoc Cancer Res 43:157, 2002.
33. Baselga J, Norton L, Massui H: Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 85:1327-1333, 1993.
34. Carpenter M, Buchsbaum DJ: Statistical growth curve modeling of tumors treated with Erbitux (IMC-C225) anti EGFR antibody, gemcitabine, and radiation (abstract 2386). Proc Am Assoc Cancer Res 43:1005-1006, 2002.
35. Cardiello F, Bianco R, Damiano V, et al: Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 5:909-916, 1999.
36. Cardiello F, Caputo R, Bianco R, et al: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6:2053-2063, 2000.
37. Raben D, Helfrich BA, Chan D, et al: ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combinationwith radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol 29(suppl 4):37-46, 2002.
38. Pollack VA, Savage DM, Baker DA, et al: Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and anti-tumor effects in athymic mice. J Pharmacol Exp Ther 291:739-748, 1999.
39. Slichenmyer WJ, Elliott WL, Fry DW: CI-1033, a pan-Erb-B tyrosine kinase inhibitor. Semin Oncol 28:80-85, 2001.
40. Xia W, Mullin RJ, Keith BR, et al: Anti-tumor activity of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21:6255-6263, 2002.
41. Busam KJ, Capodieci P, Motzer R, et al: Cutaneous side effects in cancer patients treated with anti-epidermal growth factor receptor antibody C225. Br J Dermatol 144:1169-1176, 2001.
42. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and Cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004.
43. Saltz LB, Meropol NJ, Loehrer PJ, et al: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208, 2004.
44. Badarinath S, Mitchell EP, Jennis A, et al: Cetuximab plus FOLFOX for colorectal cancer (EXPLORE): Preliminary safety analysis of a randomized phase III trial. J Clin Oncol 22:3531, 2004.
45. Venook A et al: Phase III randomized study of fluorouracil and leucovorin calcium with irinotecan or oxaliplatin and with or without cetuximab in patients with previously untreated metastatic adenocarcinoma of the colon or rectum. Cancer and Leukemia Group B Protocol 80203.
46. Alberts S, Bernath A, et al: Phase III randomized study of irinotecan (CPT-11) and/or oxaliplatin (OXAL) plus 5-fluorouracil (5-FU)/leucovorin (CF) with or without cetuximab (C225) after curative resection for patients with stage III colon cancer. North Central Cancer Treatment Group Protocol N0147.
47. Tewes M, Schleucher N, Dirrsch O, et al: Results of a phase I trial of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in patients with EGFR-expressing solid tumors (abstract 378). Proc Am Soc Clin Oncol 21:95a, 2002.
48. Shin DM, Donato NJ, Perez-Soler R, et al: Epidermal growth factor receptor-targeted with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 7:1204-1213, 2001.
49. Bruns CJ, Harbison MT, Davis DW, et al: Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 6:1936-1948, 2000.
50. Prewett M, Rockwell P, Rockwell RF, et al: The biologic effects of C225, a chimeric monoclonal antibody to EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol 19:419-427, 1996.
51. Robert F, Ezekiel MP, Spencer SA, et al: Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 19:3234-3243, 2001.
52. Kies M, Arquette M, Nabell L, et al: Final report of the efficacy and safety of the anti-epidermal growth factor antibody Erbitux (IMC-C225), in combination with cisplatin patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy (abstract 925). Proc Am Soc Clin Oncol 21:232a, 2002.
53. Baselga J, Trigo J, Bourhis J, et al: Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastaticsquamous cell carcinoma of the head and neck (SCCHN) progressing on the same dose and schedule platinum-based regimen (abstract 900). Proc Am Soc Clin Oncol 21:226a, 2002.
54 Trigo J, Hitt R, Koralewski P, et al: Ceutximab monotherapy is active in patients (pts) with platinum refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study (abstract 5502). Proc Am Soc Clin Oncol 223:487, 2004.
55. Rhoades CA, Kraut E, Schuller D, et al: Phase I and II study of OSI-774 and docetaxel in squamous cell carcinoma of the head and neck (SCCHN) (abstract 5541). Proc Am Soc Clin Oncol 23:496, 2004.
56. Burtness BA, Li Y, Flood W, et al: Phase III trial comparing cisplatin (C) + placebo (P) to C + anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastatic recurrent head and neck cancer (HNC) (abstract 901). Proc Am Soc Clin Oncol 21:226a, 2002.
57. Soulieres D, Senzer NN, Vokes EE, et al: Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 19:3267-3279, 2004.
58. Bonner JA, Giralt J, Harari PM, et al: Cetuximab prolongs survival in patients with loco-regionally advanced squamous cell carcinoma of the head and neck: A phase III study of high dose radiation therapy with or without cetuximab (abstract 5507). J Clin Oncol 22(14S):489s, 2004.
59. Kane MA, Cohen E, List M, et al: Phase II study of 250 mg gefitinib in advanced squamous cell carcinoma of the head and neck (abstract 5586). Proc Am Soc Clin Oncol 23:507, 2004.
60. Cohen EEW, Stenson K, Gustin DM, et al: A phase II study of 250-mg gefitinib (ZD1839) monotherapy in recurrent or metastatic squamous cell carcinomaof the head and neck (SCCHN) (abstract 2021). Proc Am Soc Clin Oncol 22:502, 2003.
61. Humblet Y, Vega-Villegas E, Mesia R, et al: Phase I study of cetuximab in combination with cisplatin or carboplatinand 5-fluorouracil (5-FU) in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) (abstract 5513). J Clin Oncol 22(suppl):491s, 2004.
62. Robert F, Ezekiel MP, Spencer SA, et al: Phase I study of anti-epidermal growth factor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 19:3234-3243, 2001.
63. Crombet T, Osorio M, Cruz T, et al: Use of the anti-EGFR antibody h-R3 in combination with radiotherapy in the treatment of advanced head and neck cancer (abstract 53). Proc Am Soc Clin Oncol 21:14a, 2002.
64. Cohen EE, Rosen F, Stadler WM, et al: Phase II trial of ZD1839 monotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21:1980-1987, 2003.
65. Raben D, Kane M, Song J, et al: Preliminary report on toxicity of a phase I trial of gefitinib (Iressa) in combination with radiation/chemotherapy for patients with locally advanced head and neck cancer (LAHNC). Presented at an AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, November 17-21, 2003.
66. Senzer N, Soulieres D, Siu L, et al: Phase II evaluation of OSI-774, a potent oral antagonist of EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck (abstract 6). Proc Am Soc Clin Oncol 20:2a, 2001.
67. Lillian L, Siu XC, Tsao M, et al: A phase I/II study of erlotinib (Tarceva) in combination with cisplatin in patients with recurrent or metastatic squamous cell cancerof the head and neck (HNSCC). Presented at an AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, November 17-21, 2003.
68. Herbst RS, Langer CJ: Epidermal growth factor receptors as a target for cancer treatment: The emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol 29:27-36, 2002.
69. Rosell R, Daniel C, Ramlau R, et al: Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs CV alone in first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing advanced non-small cell lung cancer (NSCLC) (abstract 7012). Proc Am Soc Clin Oncol 23:618, 2004.
70. Kim ES, Mauer AM, Tran HT, et al: A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: Final report (abstract 2581). Proc Am Soc Clin Oncol 22:642, 2003.
71. Fukuoka M, Yano S, Giaccone G, et al: Multiinstitutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol 21:2237-2246, 2003.
72. Giaccone G, Herbst RS, Manegold C, et al: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: A phase III trial-INTACT1. J Clin Oncol 22:777-784, 2004.
73. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290:2149-2158, 2003.
74. Perez-Soler R, Chachoua A, Huberman M, et al: Final results of a phase II study of erlotinib (Tarceva) monotherapy in patients with advanced non-small cell lung cancer following failure of a platinum-based chemotherapy (abstract P-611). Lung Cancer 41(suppl 2):S246, 2003.
75. Shepherd FA, Pereira J, Giulianu TE, et al: A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of first line or second line chemotheapy. A national Cancer Institute of Canada clinical trials group (NCIC CTG) trial. Presented at the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, June 5-8, 2004.
76. Herbst RS, Giaccone G, Schiller JH, et al: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 22:785-794, 2004.
77. Gatzemeier U, Pluzanska A, Szczesna A, et al: Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) (abstract 7010). Proc Am Soc Clin Oncol 23:617, 2004.
78. Herbst RS, Prager D, Hermann R, et al: TRIBUTE-a phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC) (abstract 7011). Proc Am Soc Clin Oncol 23:617, 2004.
79. Hidalgo M, Siu LL, Nemunaitis J, et al: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19:3267-3279, 2001.
80. Herbst RS, Prager D, Hermann R, et al: TRIBUTE: A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC) (abstract 7011). Proc Am Soc Clin Oncol 23:617, 2004.
81. Janas M, Bailey LR, Schmidt K, et al: Evaluation of epidermal growth factor receptor (EGFR) as a prognostic factor for survival in non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy as first-line treatment (abstract 7024). Proc Am Soc Clin Oncol 23:619, 2004.
82. Shin DM, Nemunaitis J, Zinner RG, et al: A phase I clinical and biomarker study of CI-1033, a novel pan-erb-B tyrosine kinase inhibitor in patients with solid tumors (abstract 324). Proc Am Soc Clin Oncol 20:82a, 2001.
83. Simon GR, Olson S, Garrett CR, et al: A phase I pharmacokinetic (PK) and safety study of intravenous (IV) CI-1033 in patients with advanced solid tumors (abstract 3057). Proc Am Soc Clin Oncol 23:209, 2004.
84. Wakeling AE, Guy SP, Woodburn JR, et al: ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62:5749-5754, 2002.
85. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004.
86. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004.
87. Pao W, Zakowski M, Cordon-Cardo C, et al: Molecular characteristics of non-small cell lung cancer (NSCLC) patients sensitive to gefitinib (abstract 7025). Proc Am Soc Clin Oncol 23:619, 2004.
88. Kim YH, Ishii G, Goto K, et al: Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung. Clin Cancer Res 10:7311-7317, 2004.
89. Miyoshio T, Satoh Y, Okumura S, et al: Early stage lung adenocarcinoma with a micropapillary pattern, a distinct pathologic marker for a significant poor prognosis. Am J Surg Pathol 27:101-109, 2003.
90. Janne PA: EGFR mutations predict response to gefitinib-now what? Presented at the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, June 5-8, 2004.
91. Clark G, Perez-Soler R, Siu L, et al: Rash severity is predictive of increased survival with erlotinib HCl (abstract 786). Proc Am Soc Clin Oncol 22:196, 2003.